Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform
Abstract Background The NOTI chelating scaffold can readily be derivatized for bioconjugation without impacting its metal complexation/radiolabeling properties making it an attractive building block for the development of multimeric/-valent radiopharmaceuticals. The objective of the study was to fur...
Saved in:
Main Authors: | Sebastian Martin, Moritz-Valentin Schreck, Tobias Stemler, Stephan Maus, Florian Rosar, Caroline Burgard, Andrea Schaefer-Schuler, Samer Ezziddin, Mark D. Bartholomä |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2024-12-01
|
Series: | EJNMMI Radiopharmacy and Chemistry |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41181-024-00314-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials
by: Alexander Konopnicki, et al.
Published: (2024-12-01) -
Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024-10-01) -
Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study
by: Sofía González-Rueda, et al.
Published: (2024-10-01) -
Selective light olefin synthesis with high ethylene abundance via CO2 hydrogenation over (Ga-In)2O3/SSZ-13 catalysts
by: Yasemen Kuddusi, et al.
Published: (2025-01-01) -
Real world experience with [99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry
by: Pete Tually, et al.
Published: (2024-12-01)